Abstract:Abstract Background The p38 alpha mitogen‐activated protein kinase (p38α) pathway is linked to both innate and adaptive immune responses, and is currently under investigation as a target for drug development in the context of Alzheimer’s disease (AD) and other conditions with neuroinflammatory dysfunction (Asih et al., 2020). Preclinical data indicates that p38α inhibition can protect against AD‐associated neuropathology, although the cellular mechanisms and signaling pathways that underlie these effects have not been fully elucidated. Evidence suggests that inhibition of p38α may provide benefit by modulating microglial‐associated neuroinflammatory processes that contribute to the development of AD pathology. The present study tests this hypothesis by assessing early‐stage pathological changes in AD model mice following microglial‐specific knock out (KO) of p38α. Methods KO of p38α in microglia was accomplished in 5‐month‐old C57BL/6J wild‐type and amyloidogenic AD model (APPswe/PS1dE9) mice using a tamoxifen‐inducible Cre/loxP system under control of the Cx3Cr1 promoter. Animals underwent behavioral assessment on the open field test at 7.5 months of age and on the radial arm water maze test at 11 months of age, followed by collection of cortical and hippocampal tissues. Other endpoint measures included quantification of proinflammatory cytokines, assessment of amyloid burden and plaque deposition, and characterization of microglia‐plaque dynamics using a combination of ELISA, immunohistochemical, and immunofluorescent techniques. Results Suppression of microglial p38α did not alter behavioral outcomes, proinflammatory cytokine levels, or overall amyloid plaque burden, but did significantly increase hippocampal levels of soluble Aβ42 and reduced hippocampal colocalization of Iba1 and 6E10 in a subset of microglia in close proximity to plaques. Conclusion This work suggests that rather than reducing inflammation per se, microglial p38α inhibition in the context of early AD‐type amyloid pathology may alter hippocampal microglia‐plaque interactions. Additionally, these results support future investigations of microglial p38α signaling at different stages of disease, as well as the potential relationship between p38α and phagocytic processes in this particular cell‐type. Funding : This work is supported by the National Institutes of Health (RF1 AG064859; F32 AG058456; T32 AG057461).

Blocking the CD38/cADPR Pathway Plays a Double-Edged Role in LPS Stimulated Microglia

Cd38 is A Key Enzyme for the Survival of Mouse Microglial Bv2 Cells

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Induces Microglial Nitric Oxide Production and Subsequent Rat Primary Cortical Neuron Apoptosis Through P38/jnk MAPK Pathway.

TLR4 signaling pathway mediates the LPS/ischemia-induced expression of monocytechemotactic protein-induced protein 1 in microglia

Basal Cd38/Cyclic Adp-Ribose-Dependent Signaling Mediates Atp Release and Survival of Microglia by Modulating Connexin 43 Hemichannels

Inhibition of NK1R Attenuates LPS-induced Microglial Inflammation and Consequent Death of PC12 Cells.

Inhibition of TLR4 Induces M2 Microglial Polarization and Provides Neuroprotection via the NLRP3 Inflammasome in Alzheimer’s Disease

p38 MAPK inhibits autophagy and promotes microglial inflammatory responses by phosphorylating ULK1

The role of ZC3H12D-regulated TLR4-NF-κB pathway in LPS-induced pro-inflammatory microglial activation

Characterization of Inflammatory Signals in BV-2 Microglia in Response to Wnt3a

LRP1 knockdown aggravates Aβ 1-42 -stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-κB/MAPKs signaling pathways.

LRP1 knockdown aggravates Aβ1-42-stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-κB/MAPKs signaling pathways

Cx3cl1/Cx3cr1-Mediated Microglia Activation Plays A Detrimental Role in Ischemic Mice Brain Via P38mapk/Pkc Pathway

CD38 Inhibitor 78c Attenuates Pro-Inflammatory Cytokine Expression and Osteoclastogenesis in Macrophages

LRP1 knockdown aggravates A<sub>1-42</sub>-stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-B/MAPKs signaling pathways

NMDA receptor inhibitor MK801 alleviated pro-inflammatory polarization of BV-2 microglia cells

Regulation of NLRP3 inflammasome by CD38 through cADPR-mediated Ca2+ release in vascular smooth muscle cells in diabetic mice

Inhibition of Autotaxin and Lysophosphatidic Acid Receptor 5 Attenuates Neuroinflammation in LPS-Activated BV-2 Microglia and a Mouse Endotoxemia Model

CD38 deficiency protects the retina from ischaemia/reperfusion injury partly via suppression of TLR4/MyD88/NF-κB signalling

Early loss of microglial p38α MAPK in the APPswe/PS1dE9 mouse model of Alzheimer’s disease alters soluble amyloid beta and reduces microglia co‐localization with amyloid plaques without affecting amyloid‐associated pathology

Upregulation of CCL3/MIP-1alpha regulated by MAPKs and NF-kappaB mediates microglial inflammatory response in LPS-induced brain injury